Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Ann Intern Med

Retrieve available abstracts of 16 articles:
HTML format

Single Articles

    November 2020
  1. BAILEY AL, Campbell CL
    The U.S. Department of Veterans Affairs and U.S. Department of Defense Guideline for the Management of Dyslipidemia: Is Moderate Risk Reduction Enough?
    Ann Intern Med. 2020;173:846-847.

  2. LUTZ J, Dunaj-Kazmierowska M, Arcan S, Kassner U, et al
    Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report.
    Ann Intern Med. 2020;173:764-765.

    September 2020
  3. RESTON JT, Buelt A, Donahue MP, Neubauer B, et al
    Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease : A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia.
    Ann Intern Med. 2020 Sep 22. doi: 10.7326/M20-4680.
    PubMed     Abstract available

  4. O'MALLEY PG, Arnold MJ, Kelley C, Spacek L, et al
    Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.
    Ann Intern Med. 2020 Sep 22. doi: 10.7326/M20-4648.
    PubMed     Abstract available

    August 2020
  5. TARTOF SY, Qian L, Hong V, Wei R, et al
    Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization.
    Ann Intern Med. 2020 Aug 12. doi: 10.7326/M20-3742.
    PubMed     Abstract available

    June 2020
    Scleritis With Uveal Effusion From Alirocumab.
    Ann Intern Med. 2020;172:834-836.

    May 2020
  7. LAZARTE J, Hegele RA
    Regression of Xanthelasmas With Statin Treatment in a Normolipidemic Patient.
    Ann Intern Med. 2020;172:701-702.

    April 2020
  8. UEDA M, Burke FM, Remaley AT, Hegele RA, et al
    Familial Chylomicronemia Syndrome With a Novel Homozygous LPL Mutation Identified in Three Siblings in Their 50s.
    Ann Intern Med. 2020;172:500-502.

    January 2020
  9. CARNICELLI AP, Granger CB
    In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG.
    Ann Intern Med. 2020;172:JC3.

    November 2019
  10. SMITH DA
    Review: In dyslipidemia or atherosclerotic CVD, alirocumab and evolocumab vs control each reduce MI and stroke.
    Ann Intern Med. 2019;171:JC56.

    July 2019
  11. ELHASSAN YS, Alahdab F, Prete A, Delivanis DA, et al
    Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis.
    Ann Intern Med. 2019;171:107-116.
    PubMed     Abstract available

  12. DE DIOS GARCIA-DIAZ J, Corral-Bueno IM, Mesa-Latorre JM, Lozano-Duran C, et al
    Proprotein Convertase Subtilisin/Kexin Type 9 Antibody and Statin-Associated Autoimmune Myopathy.
    Ann Intern Med. 2019;171:68-69.

    June 2019
  13. GRUNDY SM, Stone NJ
    2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline.
    Ann Intern Med. 2019;170:779-783.
    PubMed     Abstract available

    May 2019
  14. CHAIT A, Eckel RH
    The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.
    Ann Intern Med. 2019;170:626-634.
    PubMed     Abstract available

    February 2019
  15. KOEHLER P, Brockelmann PJ, Hallek M, Kochanek M, et al
    Bloodletting to Treat Severe Hypertriglyceridemia.
    Ann Intern Med. 2019 Feb 26. pii: 2726672. doi: 10.7326/L18-0706.

  16. KAZI DS, Penko J, Coxson PG, Guzman D, et al
    Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
    Ann Intern Med. 2019;170:221-229.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.